IC50: 0.68 μM (HT29); 0.6 μM (OVCAR-3); 16 μM (AsPC-1); 0.14 μM (PC-3)
LP-184 (compound 6), an acylfulvene analog, inhibits tumor growth. LP-184 has potent anti-cancer activity in the ovarian, colon, prostate and pancreatic cell lines. (patent WO2007019308A2).
LP-184 inhibits the growth of HT29, OVCAR-3, AsPC-1 and PC-3, with GI50s of 0.68, 0.6, 16 and 0.14 μM, respectively[1].
LP-184 displays IC50s of 800nM and 210 nM for anti-cancer activitie in the tmidine incorporation into cellular DNA (2 hour) and Trypan blue (48 hour) assay[1].
LP-184 (7.5 and 10 mg/kg; i.p.; 21 day) has potent 15 anti-tumor activity against MV522 tumors, producing 4/6 and 5/5 partial responses, respectively[1].
| Animal Model: | Mice (MV522 tumors) [1] |
| Dosage: | 7.5 and 10 mg/kg |
| Administration: | I.p; 21day |
| Result: | Effective agent for human anti-tumor therapy. |
[1]. Trevor C. Mcmorris, et al. Illudin analogs useful as anticancer agents. WO2007019308A2.